Update on HLA-B*15:02 allele associated with adverse drug reactions

被引：0
|
作者：
Zhu, Xueting [1 ]
Luo, Guanghua [1 ]
Zheng, Lu [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 3, Clin Med Res Ctr, Changzhou, Peoples R China
来源：
PHARMACOGENOMICS | 2024年 / 25卷 / 02期
关键词：
adverse drug reactions; antiepileptic drug; genetic marker; HLA-B*15:02; review; STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; POLYMERASE-CHAIN-REACTION; HLA CLASS-I; INDUCED MACULOPAPULAR EXANTHEMA; GENETIC-MARKERS; RISK-FACTOR; B LOCUS; CARBAMAZEPINE; HAN;
D O I：
10.2217/pgs-2023-0173
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
HLA alleles, part of the major histocompatibility complex, are strongly associated with adverse drug reactions (ADRs). This review focuses on HLA-B*15:02 and explores its association with ADRs in various ethnic populations and with different drugs, aiming to provide insights into the safe clinical use of drugs and minimize the occurrence of ADRs. Furthermore, the review explores the potential mechanisms by which HLA-B*15:02 may be associated with ADRs, aiming to gain new insights into drug modification and identification of haptens. In addition, it analyzes the frequency of the HLA-B*15:02, genotyping methods, cost-effectiveness and treatment measures for adverse reactions, thereby providing a theoretical basis for formulating clinical treatment plans.
引用
收藏
页码：97 / 111
页数：15
相关论文
共 50 条
  • [1] HLA-B*15:11 status and carbamazepine-induced severe cutaneous adverse drug reactions in HLA-B*15:02 negative Chinese
    Wong, Christina S. M.
    Yap, Desmond Y. H.
    Ip, Patrick
    Wong, Wilfred H. S.
    Chua, Gilbert T.
    Yeung, Chi-Keung
    Chan, Henry H. L.
    Kwok, Janette S. Y.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (02) : 184 - 190
  • [2] Characterization of a new HLA-B allele, B*15:179:02
    Lv, R.
    Xin, X.
    Yu, J.
    Sheng, Q.
    TISSUE ANTIGENS, 2014, 84 (06): : 586 - 587
  • [3] ASSOCIATION OF HLA-B*15:02 ALLELE WITH LAMOTRIGINE-INDUCED CUTANEOUS ADVERSE DRUG REACTION IN AN INDIAN PATIENT
    Misra, Maneesh K.
    Upchurch, Rebecca L.
    Weidner, Jerome G.
    Pullen, Bianca
    Lee, Royce
    Brown, Nicholas K.
    Marino, Susana R.
    HUMAN IMMUNOLOGY, 2019, 80 : 55 - 55
  • [4] Association between HLA-B*15:02 and carbamazepine induced severe cutaneous adverse drug reactions in Myanmar
    Khor, Amy Hui-Ping
    Aye, Seinn Mya Mya
    Lim, Kheng-Seang
    Aung, Yan Lynn
    Aye, Yin Minn
    Ohnmar
    Thit, Win Min
    Tan, Chong-Tin
    Ng, Ching-Ching
    NEUROLOGY ASIA, 2017, 22 (03) : 283 - 285
  • [5] Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population
    C-C Chang
    C-C Ng
    C-L Too
    S-E Choon
    C-K Lee
    W-H Chung
    S H Hussein
    K-S Lim
    S Murad
    The Pharmacogenomics Journal, 2017, 17 : 170 - 173
  • [6] Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population
    Chang, C-C
    Ng, C-C
    Too, C-L
    Choon, S-E
    Lees, C-K
    Chung, W-H
    Hussein, S. H.
    Lim, K-S
    Murad, S.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (02): : 170 - 173
  • [7] Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand
    Rattanavipapong, Waranya
    Koopitakkajorn, Tanunya
    Praditsitthikorn, Naiyana
    Mahasirimongkol, Surakameth
    Teerawattananon, Yot
    EPILEPSIA, 2013, 54 (09) : 1628 - 1638
  • [8] THE ENIGMA OF HLA-MEDIATED ADVERSE DRUG REACTIONS: EPOXIDE BUT NOT CARBAMAZEPINE INDUCES THE BINDING OF HAPTENATED PEPTIDES TO HLA-B*15:02
    Simper, Gwendolin S.
    Celik, Alexander A.
    Ho, Gia-Gia T.
    Huyton, Trevor
    Kuhn, Joachim
    Blasczyk, Rainer
    Bade-Doeding, Christina
    HLA, 2018, 91 (05) : 322 - 322
  • [9] HLA-B*40:02:18, a new HLA-B*40 allele
    Ko, S. -Y.
    Oh, H. -B.
    Jun, J. -H.
    Kwon, O. -J.
    TISSUE ANTIGENS, 2014, 83 (06): : 429 - +
  • [10] Characterization of the novel HLA-B*52:02:02 allele
    Zheng, Jie W.
    Xie, Jun Hua
    Sun, Ying
    Xiang, Dong
    HLA, 2021, 98 (05) : 476 - 477
12345